Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 14, Number 10—October 2008
Research

Prophylaxis after Exposure to Coxiella burnetii

Claire E. MoodieComments to Author , Herbert A. Thompson, Martin I. Meltzer, and David L. Swerdlow
Author affiliations: Centers for Disease Control and Prevention, Atlanta, Georgia, USA;

Main Article

Table 4

Summary of threshold points by group, drug efficacy, and probability of an adverse event (best estimate/upper bound estimate)

Population Drug efficacy
96.50% 40%* 82%
Primary analysis Less virulent More virulent
General population
All cases of illness 2.1/6.3 NA 2.5/7.4 3.88/11.65 1.98/5.94
Severe illness 0.08/0.24 NA 0.09/0.28 0.58/1.75 0.05/0.14
Death
0.00/1.8
NA
0.00/2.1
0.00/28.49
0.00/0.36
High-risk population
All cases of illness 2.1/6.3 NA 2.5/7.4 3.88/11.65 1.98/5.94
Severe illness 0.03/0.09 NA 0.03/0.10 0.147/0.44 0.021/0.06
Death
0.00/0.24
NA
0.00/0.28
0.00/3.5
0.00/0.05
Pregnant women
All cases of illness 4.7/13.3 11.4/32.2 5.6/15.7 9.99/28.2 4.16/11.7
Severe illness 0.002/0.006 0.005/0.014 0.002/0.007 0.0069/0.021 0.0016/0.0047
Death 0.001/0.004 0.003/0.010 0.002/0.005 0.0053/0.0156 0.0006/0.0019

*Doxycycline was not evaluated at 40% drug efficacy. NA, not available.

Main Article

Page created: July 13, 2010
Page updated: July 13, 2010
Page reviewed: July 13, 2010
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external